MABXIENCE RESEARCH SL.

Location

Madrid

Founded

2015-12-23

Risk Signals

16 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Recent Articles about MABXIENCE RESEARCH SL.

Live alerts from global media, monitored by Business Radar

FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience

2022-04-18 (prnewswire.com)

FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience

/PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which...

Read more

Never miss a headline about MABXIENCE RESEARCH SL.

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages